In 1939, the Gl261 tumor was induced by intracranial injection of 3-methylcholanthrene, cultured in vivo in C57BL/6 mice, and maintained through serial transplantation in syngeneic mouse strains. In the mid-1990s, an in vitro cell culture system was established. The literature describes cells carrying TP53 and KRAS mutations.